News

Chennai, India, November 15, 2013: Trivitron Healthcare has announced the appointment of William Mills Agency to partner the company in its national and international communication objectives. The agency will work closely in creating a national image campaign for the...

In a significant development pharmaceutical major, Ranbaxy Laboratories has received approval from the US Food and Drug Administration (FDA) to launch the generic version of Lipitor an anti-cholesterol drug in the US market. The company was expecting delay in...

Chennai, July 11, 2015: The World Health Organisation has raised concerns over data integrity of the Chennai-based clinical research organisation Quest Life Sciences based on an inspection done in October last year. The WHO said there had been failures in data...

Mumbai, April 02,2014 - The attention in the new financial year will not only be on Saugata Gupta and Varun Berry , newly appointed managing directors (MDs) of Marico and Britannia, respectively. Another recently appointed MD is vying for attention — Etienne Benet of Nestle. Benet, who took over...

New Delhi November 27, 2013: ClearPath- an American company, introduces a breakthrough technology which revolutionizes the way we treat malocclussion (straighten the teeth). ClearPath provides new improved quality 3D aligners through its unique proprietary, patented process which provides...

PAT before Exceptional Items Grows 7.4% in Fourth Quarter of FY 2012

Mumbai, Maharashtra, India, Tuesday, February 19, 2013 -- (Business Wire India) -- GlaxoSmithKline Pharmaceuticals Limited announced its financial results for the fourth quarter ended 31st December, 2012. The growth in Net Sales was 16% and Profit After Tax and before Exceptional Items was 7.4%. The core Pharmaceuticals business grew by 15.9% for the quarter.

Paris, January 25, 2019:  Pharmapack Europe (February 6-7th, Paris Expo Porte de Versailles, Paris) has released a ‘European drug delivery and packaging’ report, ahead of the event’s opening which highlights, major challenges and opportunities for the industry in the year ahead. The...

New Delhi, May 19, 2018: SAP Gold Partner T.CON successfully carried out the system conversion from SAP ERP to SAP S/4HANA version 1709 in only one step at Perlen Packaging, a subsidiary of Chemie + Papier Holding AG (CPH)....

‘PATIALA AGAINST DRUGS’, an awareness drive on Drug Abuse  Patiala, February 17, 2014: Drug usage for recreation leads to addiction and once somebody comes under the grip, it is extremely difficult for them to get rid of it. The addiction...

Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Actavis, Inc., which was acquired by Watson in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market bortezomib.

Actavis' ANDA product is a generic version of Millennium Pharmaceuticals' Velcade ® (bortezomib), which is a proteasome inhibitor, for intravenous or subcutaneous administration, approved for the treatment of patients with multiple myeloma and patients with mantle cell lymphoma who have received at least one prior therapy.